Basilea Pharmaceutica Ltd, which specialises in treating bacterial and fungal infections, has proposed that Nicole Onetto be appointed as a non-executive director at the company’s annual general meeting on 27 April. Dr Onetto, who has dual French and Canadian nationality, currently is a consultant on oncology, drug development and translational research in Vancouver. Until recently, she was deputy director and chief scientific officer at the Ontario Institute for Cancer Research in Toronto. She holds an MD from the University of Paris and a Master of Pharmacology from the University of Montreal. She is currently on the board of ProNAi Therapeutics, a Vancouver-based oncology haematology company. The appointment coincides with Basilea’s decision to advance its oncology portfolio
Basilea announced the appointment on 27 February 2017.
Copyright 2017 Evernow Publishing Ltd